Abstract 15680: Comparative Renal Safety and Efficacy of Baxdrostat vs Lorundrostat in Hypertensive Patients: A Systematic Review and Network Meta-Analysis
Background: Hypertension remains a major therapeutic challenge with significant morbidity, requiring novel pharmacological options. Selective aldosterone synthase inhibitors (ASIs), particularly baxdrostat and lorundrostat, offer a potent approach to blood pressure control. However, their comparative renal safety pr...